A Significant Milestone in Cancer Treatment The landscape for treating rare bile duct cancers has shifted with the recent FDA approval of Lyrfigtu (lirafugratinib). This new medication offers a targeted therapeutic option for adult patients battling cholangiocarcinoma, a challenging malignancy of the bile ducts. Understanding Lyrfigtu Lyrfigtu is specifically designed for patients who have previously…